At Nautilus we strive to stay at the cutting edge of developments in the proteomics space. We constantly learn from proteomics researchers so we can work to provide the most effective solutions to those who are leveraging the proteome for applications in basic research, human health, and beyond.
Toward this end, we are excited to attend HUPO 2022 in Cancun Mexico, December 4th – 8th. Nautilus team members will be on hand to answer your questions about the Nautilus platform and share early data showing how the platform is designed to enable deeper access to the proteome. We hope to see you there!
Discover Nautilus’ technology and meet the experts developing it
Nautilus Booth 102 will be staffed by various members of the Nautilus team who will give you the run-down on the science behind Nautilus. At the booth, you’ll also have the opportunity to meet Nautilus Co-Founder and Chief Scientist, Parag Mallick, and VP of Affinity Reagent Development, Sheri Wilcox at our “Meet the Expert” sessions (3:30PM, December 5-7). Parag and Sheri will walk you through our approach to single-molecule proteomics and answer any questions you have about the technology. Learn more about Parag and Sheri in their bios below.
Dr. Parag Mallick is a Nautilus Founder, our Chief Scientist, and an Associate Professor at Stanford University. Originally trained as an engineer and biochemist, his research spans computational and experimental systems biology, cancer biology, and nanotechnology. Dr. Mallick received his Ph.D. from UCLA, where he worked with Dr. David Eisenberg. He completed post-doctoral studies at The Institute for Systems Biology, in Seattle, WA with Dr. Ruedi Aebersold. Beyond studying fundamental disease mechanisms, his group has been pioneering big-data approaches for enabling personalized and predictive medicine. In addition to his academic training, Dr. Mallick is also an accomplished magician. He is a member and frequent performer at the prestigious Magic Castle in Hollywood. He has performed all over the world for clients ranging from A-List Celebrities to Fortune 500 companies.
Sheri Wilcox, Ph.D., joined Nautilus from SomaLogic, where she was instrumental in the development of the SomaScan Platform and SOMAmer reagents over 21 years at the company and most recently served as Senior Director of Global Scientific Engagement. Dr. Wilcox advanced through positions of increasing responsibility at SomaLogic, including Associate Director of Aptamer Discovery where she guided research of aptamers for biomarker discovery and directed the high-throughput generation of SOMAmer reagents, and Senior Director of Analytical and Discovery Sciences, leading SOMAmer discovery and characterization efforts, as well as several collaborations. Before joining SomaLogic, she applied mass spectrometric methods to understanding antibiotic resistance as a postdoctoral fellow at Pharmacia, prior to its merger with Pfizer Inc. Dr. Wilcox received her B.S. in chemistry from Vanderbilt University, and her Ph.D. in macromolecular and cellular structure and chemistry from Scripps Research.
Nautilus lunch seminar – Unleashing Single-Molecule Proteomics at Scale
Click here to register for our lunch seminar “Unleashing Single-Molecule Proteomics at Scale” at 1:15 PM on Tuesday, December 6th in Gran Cancun 4. During the seminar you will:
- Learn more about Nautilus and the technology behind our novel single-molecule proteomics platform from Nautilus Co-Founder and Chief Scientist Parag Mallick, PhD.
- Hear thoughts on the state of the field and potential applications of single-molecule proteomics from Ruedi Aebersold, PhD, Professor of Systems Biology, Institute of Molecular Systems Biology in ETH Zurich and Philip Lorenzi, PhD, Associate Professor, MD Anderson Cancer Center.
Nautilus posters and presentations at HUPO 2022
You can learn more about Nautilus’ technology and its applications at our posters or stop by Sheri Wilcox’s presentation detailing our unique approach. We’ll cover everything ranging from the development of multi-affinity probes to the analysis of key biomarkers in Alzheimer’s disease:
- CS06: Development and Characterization of Multi-Affinity Probes for Protein Identification by Short-epitope Mapping. Monday, Dec 5th 4:25–4:35 PM, Sheri Wilcox, PhD, Nautilus Biotechnology
- PP01.40: Development and Characterization of Multi-Affinity Probes for Protein Identification by Short-epitope Mapping. Monday, Dec 5th 11:45 AM-1:00 PM, Sheri Wilcox, PhD, Nautilus Biotechnology
- PP03.50: Computational Modeling of Protein Identification by Short-epitope Mapping (PrISM). Wednesday, Dec 7th 11:45 AM-1:00 PM, Jarrett Egertson, PhD, Nautilus Biotechnology
- PP03.51: Delivering Comprehensive, Single-molecule Proteomics Using Protein Identification by Short-epitope Mapping (PrISM). Wednesday, Dec 7th 11:45 AM-1:00 PM, Parag Mallick, PhD, Nautilus Biotechnology
- PP03.61: Defining Tau Splicing Isoforms and Phosphoforms at the Single-Molecule Level. Wednesday, Dec 7th 11:45 AM-1:00 PM, Greg Kapp, PhD, Nautilus Biotechnology
- PP03.68: PARP1 proteoform heterogeneity is associated with response to PARP1 inhibition. Wednesday, Dec 7th 11:45 AM-1:00 PM, Philip Lorenzi, PhD, MD Anderson Cancer Center
- PP03.69: High-density and scalable protein arrays for single-molecule proteomic studies. Wednesday, Dec 7th 11:45 AM-1:00 PM, Sheri Wilcox, PhD, Nautilus Biotechnology
The Nautilus Single-molecule Proteomics First Access Challenge
At our booth, you can also learn more about our Single-molecule Proteomics First Access Challenge. We’re inviting researchers to become the first to access our Proteome Analysis platform and reimagine what is possible in proteomics when they use Protein Identification by Short-epitope Mapping (PrISM) to easily and sensitively measure billions of intact single-molecule proteins.
To enter the challenge, you must do the following by February 10th, 2023:
- Fill out a short questionnaire
- Submit an abstract (500 words or less) describing the type of experiment you would run if you could measure the proteome using PrISM on 12 samples
- Submit a description of the impact your research will have in terms of improving scientific knowledge, understanding disease, or impacting the science research community in some other way
Three winners will be announced at US HUPO in Chicago, IL March 4th-8th, 2023. For the winners Nautilus will:
- Analyze 12 of your samples using Nautilus’ Proteome Analysis Platform
- Provide you with a final report of data from that analysis, in an easy-to-interpret format
- Reimburse the winner’s travel expenses to present your interesting Nautilus data at a mutually agreed upon conference
- Assist you in writing and submitting your Nautilus data in peer reviewed scientific journals
Find more information including a detailed FAQ here.
We look forward to seeing you at HUPO 2022!
Proteomics could unlock how tau protein and Alzheimer’s are linked
Learn about the links between tau and Alzheimer's and find out how we're using the Nautilus platform to better understand their connections.
Three takeaways from HUPO 2022 in Cancun Mexico
In this blog post we share our 3 key proteomics take aways from our incredible time at HUPO 2022 in Cancun Mexico.